PT - JOURNAL ARTICLE AU - Alexis Darras AU - Kevin Peikert AU - Antonia Rabe AU - François Yaya AU - Greta Simionato AU - Thomas John AU - Anil Kumar Dasanna AU - Semen Buvalyy AU - Jürgen Geisel AU - Andreas Hermann AU - Dmitry A. Fedosov AU - Adrian Danek AU - Christian Wagner AU - Lars Kaestner TI - Bloody jello: Colloidal physics states acanthocyte sedimentation rate as a diagnostic biomarker for neuroacanthocytosis AID - 10.1101/2020.09.01.20185041 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.01.20185041 4099 - http://medrxiv.org/content/early/2020/10/26/2020.09.01.20185041.short 4100 - http://medrxiv.org/content/early/2020/10/26/2020.09.01.20185041.full AB - Chorea-acanthocytosis and McLeod syndrome are the core diseases among the group of rare neurodegenerative disorders called neuroacanthocytosis syndrome (NAS). NAS patients have irregularly spiky erythrocytes, so-called acanthocytes. Their detection is a crucial but error-prone parameter in the diagnosis of NAS, often leading to misdiagnosis. Based on the standard Westergren method, we show that the acanthocyte sedimentation rate (ASR) with a two-hour read-out is significantly prolonged in Chorea-acanthocytosis and McLeod syndrome without overlap compared to the erythrocyte sedimentation rate (ESR) of controls. Thus, the ASR/ESR is a clear, robust and easily obtained diagnostic marker. Mechanistically, through modern colloidal physics, we show that acanthocyte aggregation and plasma fibrinogen levels slow down the sedimentation. This study is also a hallmark of the physical view of the erythrocyte sedimentation by describing anticoagulated blood in stasis as a percolating gel, allowing the application of colloidal physics theory.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (DFG) in the framework of the research unit FOR 2688 "Instabilities, Bifurcations and Migration in Pulsatile Flows", by the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860436 - EVIDENCE and by the Saarland University competitive funding (Forchungsausschuss). K.P. was supported by the Else Kroener Clinician Scientist Program (TU Dresden, Germany) and the Rostock Academy for Clinician Scientists (RACS, University of Rostock, Germany), A.H. is supported by the "Hermann und Lilly Schilling-Stiftung fuer medizinische Forschung im Stifterverband". F.Y., T.J. and C.W. acknowledge funding from French German University (DFH / UFA). We are indebted to the Advocacy for Neuroacanthocytosis Patients (www.naadvocacy.org) for financial support for chorea Western blotting. We also gratefully acknowledge the computing time granted through JARA-HPC on the supercomputer JURECA at Forschungszentrum Juelich. We would like to thank Alexander Kihm and Dr. Hannes Glass for help in obtaining blood samples, their handling and transportation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this research was provided by the "Ethikkommission bei der Aerztekammer des Saarlandes" (Ethical Committee of the Saarland Medical Chamber).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost of the data generated and/or analyzed during this study are present in the paper or the Supplementary Figures. Intermediate technical results or newly design analyses software is available upon reasonable request to the corresponding authors.